Chest
-
Randomized Controlled Trial Comparative Study Clinical Trial
Pulmonary function and sputum production in patients with cystic fibrosis: a pilot study comparing the PercussiveTech HF device and standard chest physiotherapy.
To compare the PercussiveTech HF (PTHF) device (Vortran Medical Technology 1; Sacramento, CA) to standard manual chest physiotherapy (CPT) with respect to acute changes in pulmonary function, sputum production, and pulse oximetry in patients with cystic fibrosis (CF). ⋯ The PTHF device appears to be a safe and effective method of airway clearance in CF patients in this small pilot study.
-
Randomized Controlled Trial Clinical Trial
Office spirometry significantly improves early detection of COPD in general practice: the DIDASCO Study.
To determine if spirometry is essential for the early detection of COPD in general practice, compared to the screening value of a short questionnaire. ⋯ The use of a spirometer is mandatory if early stages of OLD are to be detected in general practice. Screening for airflow obstruction almost doubles the number of known patients with OLD.
-
Randomized Controlled Trial Clinical Trial
Symptoms, respirator use, and pulmonary function changes among New York City firefighters responding to the World Trade Center disaster.
New York City firefighters responding to the World Trade Center (WTC) disaster on September 11, 2001, were exposed to numerous hazards. A medical screening program was conducted 3 weeks after the disaster on a sample of firefighters. ⋯ The symptoms and pulmonary function changes following exposure at the WTC demonstrate the need for improvements in respirators and their use, as well as long-term medical monitoring of rescue workers.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma.
To determine baseline characteristics predictive of response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. ⋯ Patients who benefit most when omalizumab is administered as add-on therapy are those receiving high doses of BDP, those with a history of frequent emergency asthma treatment, and those with poor lung function. Patients should be treated with omalizumab for a minimum duration of 12 weeks.
-
Randomized Controlled Trial Clinical Trial
Repeated dosing effects of mediator antagonists in inhaled corticosteroid-treated atopic asthmatic patients.
The anti-inflammatory effects of repeated dosing with mediator antagonists as add-on therapy to that with inhaled corticosteroids (ICSs) in patients with asthma remain to be fully established. ⋯ Repeated dosing with FEX and ML as add-on therapy improved AMP PC(20) and other surrogate inflammatory markers along with asthma diary outcomes in ICS-treated atopic asthmatic patients. Further studies are indicated to evaluate the long-term add-on effects of FEX on asthma exacerbations.